The Phase II trial (NCT01676649) examined the safety and efficacy of ipilimumab plus carboplatin/paclitaxel for advanced melanoma (NRASmut: n = 2, BRAFmut: n = 8, NRAS/BRAFmut: n = 1, NRAS/BRAFwt: n = 19) [455].Mutations in NRAS/BRAF were more frequently observed in patients with PD compared with the patients who achieved clinical benefit (nine out of 17 vs. Here, BRAF is linked to melanoma.